Research Topics
Species | Unn Merete FagerliSummaryAffiliation: Norwegian University of Science and Technology Country: Norway Publications
| Collaborators
|
Detail Information
Publications
Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cellsUnn Merete Fagerli
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway
Blood 111:806-15. 2008..In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells...
Hepatocyte growth factor promotes migration of human myeloma cellsRandi Utne Holt
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, MTFS, N 7489 Trondheim, Norway
Haematologica 93:619-22. 2008..Hepatocyte growth factor-mediated migration was dependent on phosphatidylinositol-3-kinase, involved the MAPK/Erk signaling cascade and VLA-4 integrins, but did not involve Akt, mTOR or G proteins...
A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cellsHåkon Hov
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Clin Cancer Res 10:6686-94. 2004..We wanted to examine the role of the hepatocyte growth factor (HGF) receptor c-Met in multiple myeloma by applying a novel selective small molecule tyrosine kinase inhibitor, PHA-665752, directed against the receptor...
Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell diseaseKarin F Wader
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Histopathology 60:443-51. 2012..Our aims were to investigate whether HGF and c-Met are present in bone marrow and extramedullary tumours from patients with monoclonal plasma cell disease, and whether c-Met is activated...
High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosisAnne Tove Brenne
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Eur J Haematol 82:354-63. 2009..BCL3 is a putative oncogene encoding for a protein belonging to the inhibitory kappaB-family. We experienced that this putative oncogene was a common target gene for growth-promoting cytokines in myeloma cell lines...
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myelomaTherese Standal
Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Blood 109:3024-30. 2007..45, P = .008), in sera from 34 patients with myeloma. These observations suggest that HGF inhibits bone formation in multiple myeloma...
Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parametersKarin F Wader
Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim
Eur J Haematol 87:394-9. 2011..We examined serum levels of soluble c-Met in patients with myeloma and healthy individuals and investigated a possible relationship with clinical disease parameters and survival...
c-Met signaling promotes IL-6-induced myeloma cell proliferationHåkon Hov
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Eur J Haematol 82:277-87. 2009..We therefore wanted to investigate if HGF could influence the effects of interleukin (IL)-6...
